You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
郭思治: 大市跌勢似未休 小雙底之支持面臨考驗
香港股票分析師協會副主席郭思治稱,昨天(6日)大市再進一步受壓,恆指早市先輕微低開7點至28,136點,其後再進一步跌至27,904點方漸見喘定,即其時大市再急回239點,由於沽壓漸消,加上伺低吸納之買盤略作主動,故市勢得以反彈,但在買盤薄弱下,恆指升至28,151點已漸受規限,而整個大市亦再次重陷反覆拉鋸之中,恆指最後報收28,072點,較上日再跌70點,全日總成交金額則稍減至1448億元,從走勢上看,大市自上週一高位29,394點開始之回落,至昨天低位27,904點止計,在連跌6日後,累積之跌幅已達1,490點,論跌幅該不算少,故市勢略作後抽亦屬正常,照目前之形勢看,大市如能作較明顯之反彈,首個上升阻力位該爲20天線(28,687點)及10天線(28,691點),大市如欲擺脫進一步尋底之威脅,恆指必需先重越上述兩組平均移動線並穩守其上,否則,一旦沽壓再現,恆指將進一步下試小雙底。

國家藥品監督管理局藥品審評中心發佈了(以臨牀價值爲導向的抗腫瘤藥物臨牀研發指導原則)的徵求意見稿,可以理解爲「未來將嚴格限制低效重複的所謂國內創新藥」,對目前估值稍偏高的藥業股當帶來打擊,由於政策已出,故對藥業之版塊暫宜先稍抱觀望,至於有利在手者,最好當然是先行回吐。

(筆者爲證監會持牌人)~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account